News

Anxiety is common among people newly diagnosed with amyotrophic lateral sclerosis (ALS) and their family members, a small study from Sweden reports. However, symptoms of anxiety tended to ease about six or so months later for patients, while they continued to affect relatives, many who are caregivers, two years…

A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS) is expected to launch in the coming months, according to the therapy’s developer, Verge Genomics. Verge also announced that the upcoming trial will use Modality.AI, a…

Health Canada has cleared ProJenX to open the third part of its ongoing Phase 1 clinical trial and begin testing the experimental therapy prosetin in people with amyotrophic lateral sclerosis (ALS). The first two parts of the PRO-101 trial (NCT05279755) involved healthy participants and showed that the…

A test that assesses the electrical activity associated with blinking may help speed the diagnosis of amyotrophic lateral sclerosis (ALS) and monitor disease progression in people with the condition, a study found. Findings showed that certain electrical waves can significantly distinguish people with ALS from healthy controls or…

A neuroscientist with a specialty in amyotrophic lateral sclerosis (ALS) is joining the faculty at Vanderbilt University Medical Center (VUMC) and will establish an ALS research center at the Nashville school. Véronique Belzil, PhD, whose work is focused on developing tailored treatments for people with ALS, also will serve…

Scientists have created new “molecular traps” that were able to improve survival in cell and fruit fly models of amyotrophic lateral sclerosis (ALS) associated with mutations in the gene C9ORF72. The traps bind to the toxic small proteins that arise from the mutated C9ORF72 gene and have a harmful…

The U.S. Food and Drug Administration (FDA) soon will meet with BrainStorm Cell Therapeutics to discuss the company’s plans for a confirmatory Phase 3b trial of NurOwn in people with amyotrophic lateral sclerosis (ALS). The expedited, face-to-face meeting is scheduled for Dec. 6, less than two months…

A partnership between LifeArc and the UK Dementia Research Institute (UK DRI) is awarding £14.5 million (about $18.2 million) to seven research projects aimed at developing new tests, treatments, and devices for neurodegenerative diseases. “Our partnership with UK DRI allows us to identify and back the most promising translational…

Toxic compounds produced by cyanobacteria, which have been identified as risk factors for developing amyotrophic lateral sclerosis (ALS), were detected in air and earth samples collected around the Great Salt Lake in Utah, a study reports. “An understanding of the types and concentrations of cyanotoxins present in air is…

VectorY Therapeutics has raised about $138 million in funding aiming to bring into clinical testing VTx-002, its lead treatment candidate for amyotrophic lateral sclerosis (ALS). The therapy equips nerve cells to produce antibodies against the damaging TDP-43 protein clumps that are an ALS hallmark. “The investment…